Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in New York that specializes in developing innovative therapies for hematologic malignancies, particularly in the realms of bone marrow transplantation and adoptive cell therapies. Leveraging its proprietary antibody-radionuclide conjugate platform, Actinium is committed to enhancing patient outcomes and addressing critical unmet needs in oncology. With a robust pipeline of therapeutic candidates and strategic partnerships, the company stands out as a promising investment opportunity for institutional investors looking for growth and innovation in the biopharmaceutical sector.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

100 PARK AVENUE, NEW YORK, NY, UNITED STATES, 10017

December

$43.4 Million

-$37.1 Million

0.0

-1.11

$0.00

0.0%

-0.3